What to Expect Your First Month on a GLP-1

The first month on a GLP-1 is the month most people misread. They expect it to be a preview of the results, and it is really a tolerance test.

Here is what the labels and the trial data actually describe, and what is genuinely unknown.

Why is the starting dose so low?

Because it is not meant to work yet.

The Zepbound label says it plainly: the 2.5 mg starting dosage “is for treatment initiation and is not approved as a maintenance dosage” [1]. The approved maintenance doses for weight reduction are 5 mg, 10 mg or 15 mg [1]. Wegovy starts at 0.25 mg weekly, and the usual maintenance dose is 2.4 mg, roughly ten times higher [2].

The reason is written into every label in the class. The escalation schedule exists “to reduce the risk of gastrointestinal adverse reactions” [1][2]. Your gut needs time to adapt before the drug reaches a dose that produces meaningful weight change.

So if the first four weeks feel underwhelming, that is the design working as intended, not a sign the medicine has failed.

What does the escalation schedule look like?

It depends entirely on which product you were given.

Wegovy injection runs on a fixed 16-week ladder before maintenance [2]:

Weeks	Weekly dose
1 to 4	0.25 mg
5 to 8	0.5 mg
9 to 12	1 mg
13 to 16	1.7 mg
17 onward	1.7 mg or 2.4 mg maintenance

For adults who tolerate 2.4 mg for at least four weeks and need additional weight reduction, the dosage may be increased to a maximum of 7.2 mg weekly [2].

Zepbound starts at 2.5 mg weekly for four weeks, then moves to 5 mg, and may increase in 2.5 mg steps after at least four weeks on the current dose, up to a maximum of 15 mg [1].

Wegovy tablets run on 30-day steps: 1.5 mg for days 1 to 30, 4 mg for days 31 to 60, 9 mg for days 61 to 90, then 25 mg maintenance [2].

Foundayo (orforglipron) starts at 0.8 mg daily, moves to 2.5 mg after at least 30 days, then 5.5 mg, and may step up to 9 mg, 14.5 mg or 17.2 mg at 30-day minimum intervals [3].

Saxenda is the outlier: a daily injection starting at 0.6 mg per day for one week, increasing at weekly intervals to 3 mg daily. The label notes pediatric escalation may take up to 8 weeks, and that pediatric patients who do not tolerate 3 mg daily may have the dosage reduced to 2.4 mg daily [4].

Note that every one of these is a minimum interval, not a mandatory step. Wegovy’s label says that if a patient does not tolerate a dose during escalation, consider delaying escalation for four weeks [2].

What side effects are common in the first weeks?

The pooled Zepbound weight trials give the clearest picture, comparing 2,519 treated patients against placebo [1]:

Side effect	Zepbound 5 to 15 mg	Placebo
Nausea	25 to 29%	8%
Diarrhea	19 to 23%	8%
Constipation	11 to 17%	5%
Vomiting	8 to 13%	2%
Abdominal pain	9 to 10%	5%
Indigestion (dyspepsia)	9 to 10%	4%
Injection site reactions	6 to 8%	2%
Fatigue	5 to 7%	3%
Burping (eructation)	4 to 5%	1%
Hair loss	4 to 5%	1%

Overall, gastrointestinal reactions occurred in 56 percent of Zepbound-treated patients versus 30 percent on placebo [1]. The label adds the timing detail that matters most for a first-month reader: “The majority of nausea, vomiting, and/or diarrhea events occurred during dose escalation and decreased over time” [1].

Severe gastrointestinal reactions were less common but real: 1.7 percent at 5 mg, 2.5 percent at 10 mg and 3.1 percent at 15 mg, versus 1 percent on placebo [1]. The label states Zepbound is not recommended in patients with severe gastroparesis [1].

How many people stop in the first few months?

More than people expect, and mostly for the same reason.

Across the two pooled Zepbound weight trials, 4.8 percent (5 mg), 6.3 percent (10 mg) and 6.7 percent (15 mg) of treated patients permanently discontinued because of adverse reactions, compared with 3.4 percent on placebo [1]. The label says “the majority of patients who discontinued ZEPBOUND due to adverse reactions did so during the first few months of treatment due to gastrointestinal adverse reactions” [1].

Real-world persistence is worse than trial persistence. A 2026 narrative review in Current Diabetes Reports synthesizing seven real-world studies found 12-month persistence ranging from 32.8 percent to 51.0 percent depending on how allowable refill gaps were defined, and discontinuation reaching 64.1 percent at two years in one large cohort. Adverse effects were the most commonly reported reason for stopping, with gastrointestinal events associated with a higher discontinuation hazard; older age, lower income and less weight reduction during therapy were also associated with stopping [5]. The same review notes that nearly half of patients restarted therapy within the first year, so stopping is often a pause rather than an ending, and that none of the included studies described structured behavioral or supportive strategies — so the review cannot say how much of this is modifiable [5].

How much weight will I lose in the first month?

Honestly: the trials do not answer this, and anyone who gives you a confident number is guessing.

The pivotal Wegovy adult studies escalated to 2.4 mg over 16 weeks, followed by a 52-week maintenance period, with results measured at 68 weeks [2]. Zepbound’s trials ran 72 weeks [1]. The primary endpoints sit more than a year out, after months at the treatment dose.

What the trial design tells you is that month one is before the drug is doing its main work. Individual first-month change varies enormously and is influenced by water weight, starting point, diet changes and normal fluctuation.

It is also worth saying clearly: this site does not publish before-and-after framing for a reason. First-month numbers shared in community forums are self-reported, unverified, and selected by who chose to post.

Should I move up to the next dose at four weeks?

That is a conversation, not a default.

The ADA’s 2026 Standards of Care recommendation 8.20 says to “individualize the dose and the dose titration approach of obesity pharmacotherapy to balance effectiveness, health benefits, and tolerability,” and states directly that “the optimal treatment dose may not be the maximum approved dose” [6]. The Zepbound label similarly instructs prescribers to consider treatment response and tolerability when selecting the maintenance dosage, and to consider a lower maintenance dosage if a higher one is not tolerated [1].

This is a live topic in patient communities. In one widely read r/Zepbound thread, a poster twenty weekly doses into treatment while still on 2.5 mg wrote: “Don’t be in a rush to dose up… Especially if you are losing weight on 2.5mg, there is no need to immediately dose up! Have a gameplan with your doctor” [7]. Others in the same thread described staying at the starting dose partly because higher doses cost more on some self-pay ladders [7].

That is community experience, not guidance. What to do about your own dose is a decision for you and your prescriber.

What do I do if I miss a dose?

This is the most product-specific thing in the first month, and it is where people most often assume one product’s rule applies to another. What follows is what each label’s “Recommendations Regarding Missed Dose” section says, not instructions for your own case.

• Wegovy injection: the label directs that if the next scheduled dose is more than 2 days away the missed dose be administered as soon as possible, and that if it is less than 2 days away the dose be skipped and dosing resumed on the regular day. If 2 or more consecutive doses are missed, the label directs reinitiating dosage escalation at a lower dosage [2].
• Wegovy tablets and oral semaglutide (Rybelsus, Ozempic tablets): the labels direct skipping the missed dose and taking the next dose the following day [2][10].
• Zepbound: the label gives a 4-day (96-hour) window after the missed dose, and says to skip it beyond that. The weekly day can be changed as long as doses are at least 3 days (72 hours) apart [1].
• Ozempic injection: the label directs administration within 5 days of the missed dose [8].
• Trulicity: the label directs taking the missed dose as soon as possible if at least 3 days (72 hours) remain before the next scheduled dose [11].
• Saxenda: the label directs resuming the once-daily regimen at the next scheduled dose without an extra or increased dose, and reinitiating at 0.6 mg daily with the full escalation schedule if more than 3 days have elapsed since the last dose [4].
• Foundayo: the label directs taking the missed dose as soon as possible and not doubling the next dose, and reinitiating escalation at a lower dosage if 7 or more consecutive doses are missed [3].

Every one of those is a label instruction to the prescriber and patient, and every product is different. Your own Instructions for Use, prescription and prescriber govern what you do.

What are the practical things nobody warns you about?

A few label details that turn into first-month friction:

Injection training is required, not optional. Both labels say the prescriber must train you or your caregiver on proper injection technique for your specific device before initiation, and retrain if the device changes [1][2]. The Zepbound KwikPen and Wegovy FlexTouch pen are not recommended for self-administration by people who are visually impaired [1][2].

Rotate sites and inspect the solution. Both labels instruct rotating injection sites with each dose and inspecting the solution before use; it should be clear and colorless, or slightly yellow for Zepbound [1][2].

Never share a multi-dose pen. Both labels carry a specific warning against sharing a pen between patients even if the needle is changed, because of blood-borne pathogen risk [1][2].

Oral timing is strict for semaglutide tablets. Wegovy tablets, Rybelsus and Ozempic tablets are labeled to be taken on an empty stomach in the morning with no more than 4 ounces of water, swallowed whole, with at least 30 minutes before food, other drinks or other oral medicines [2][10]. Foundayo has none of those timing rules and is labeled to be taken with or without food [3]. Foundayo has a different constraint instead: its label caps the dosage at 9 mg once daily when taken with a strong CYP3A4 inhibitor and advises avoiding strong CYP3A4 inducers, so the medication list matters more for it than the breakfast schedule does [3].

Tell other clinicians. Both labels warn about rare reports of pulmonary aspiration during general anesthesia or deep sedation in patients on GLP-1 receptor agonists who had residual stomach contents despite reported fasting, state that available data are insufficient to recommend how to mitigate the risk, and instruct patients to inform healthcare providers about any planned surgery or procedure [1][2].

Birth control may need a backup. The Zepbound label advises patients using oral contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and for 4 weeks after each dose increase [1].

When should I call instead of waiting?

The labels name the situations that should not be waited out [1][2]:

• Persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting. This is the pancreatitis signal, and both labels say to discontinue if pancreatitis is suspected.
• Symptoms suggesting gallbladder disease.
• Vomiting or diarrhea severe enough to cause dehydration. Both labels warn about acute kidney injury from volume depletion, especially during initiation and escalation.
• Signs of a serious allergic reaction such as swelling or trouble breathing.
• Low blood sugar symptoms, particularly if you also take insulin or a sulfonylurea.
• A lump in the neck, trouble swallowing, shortness of breath or persistent hoarseness, which the boxed warning lists as possible thyroid tumor symptoms.

None of this is a substitute for talking to a clinician. It is a list of the things the label itself treats as urgent.

What should the first month actually look like?

A reasonable frame:

• Week 1: first dose, injection training if you have not had it, note how you feel in the 48 hours after.
• Weeks 2 to 3: the labels report that most nausea, vomiting and diarrhea occurred during dose escalation [1]. Both labels also warn about acute kidney injury following volume depletion from those reactions, which is why dehydration is treated as a reportable problem rather than a minor one [1][2].
• Week 4: the point at which the labels’ minimum escalation interval is first reached, which is why this is the usual moment for a tolerability conversation with the prescriber [1][2].
• Throughout: eating patterns, protein intake and activity are what the guidelines expect to run alongside the drug. ADA recommends nutrition, physical activity and behavioral therapy alongside medication, with high-frequency counseling of 16 or more sessions over six months where available [6]. A 2026 JMIR analysis warned that telehealth platforms often do not supply this support, and that some patients lose lean tissue as a result [9].

The first month is not the result. It is the setup.

Everything above describes what the FDA-approved prescribing information, the accompanying Instructions for Use, and published guidelines say. It is not a dosing plan. Follow the prescription you were given, the Instructions for Use packaged with your specific product and device, and the prescriber who wrote it.

Sources

1. ZEPBOUND (tirzepatide) injection — US Prescribing Information, Eli Lilly
2. WEGOVY (semaglutide) injection and tablets — US Prescribing Information, DailyMed
3. FOUNDAYO (orforglipron) tablets — US Prescribing Information, DailyMed
4. SAXENDA (liraglutide) injection — US Prescribing Information, DailyMed
5. Persistence in GLP-1-Based Therapy Among Adults with Obesity and Type 2 Diabetes, Current Diabetes Reports 2026
6. American Diabetes Association, Section 8: Obesity and Weight Management, Standards of Care in Diabetes–2026
7. r/Zepbound, “Just did my 20th shot on 2.5mg. Here’s 10 things I’ve learned so far.”
8. OZEMPIC (semaglutide) injection — US Prescribing Information, DailyMed
9. After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care, JMIR 2026
10. RYBELSUS and OZEMPIC (oral semaglutide) tablets — US Prescribing Information, DailyMed
11. TRULICITY (dulaglutide) injection — US Prescribing Information, DailyMed